FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2898117984> ?p ?o ?g. }

• W2898117984 endingPage "S701" @default.
• W2898117984 startingPage "S700" @default.
• W2898117984 abstract "Programmed death 1 ligand-1(PD-L1) is important regulators in cancer immunity. The aim of this study was to evaluate the values of the expression of the soluble programmed death-1(sPD-L1) in the plasma of patients with lung cancer, and to investigate the associations between the expression level of sPD-L1 and clinicopathological features as well as effective and survival outcomes. A total of 200 patients with non-small cell lung cancer (NSCLC)(n=188) and small cell lung cancer(SCLC)(n=12) treatment naive were explored, 96 samples of healthy subjects and 13 samples of benign tumours were studied as control. The sPD-L1 expression was scored by the way of anenzyme-linked immunosorbent assay (ELISA). We followed up 67 patients with NSCLC before and after standard treatment, and blood samples were taken every two months. We compared sPD-L1 expression with clinicopathological features and patients outcomes. The Expression of sPD-L1 in patients of lung cancer was significantly higher than benign tumour group and healthy group (3.01±3.00ng/ml, 1.76±1.74ng/ml, 1.82±1.20ng/ml, P=0.002). The level of sPD-L1 in lung cancer was not associated with gender, age, smoking history, and histologic subtypes (P＞0.05). The level of sPD-L1 was significantly higher in patients of worse PS (performance status)(PS≥2) than better PS(PS<2) (6.40±6.53 vs. 2.68±2.06 P=0.005). The level of sPD-L1 with later stages were remarkable higher than earlier stages (P<0.001) in NSCLC patients. The expression of sPD-L1 of the patients with epidermal growth factor (EGFR) mutated adenocarcinoma was higher than EGFR-wild group (4.30±1.82ng/ml vs. 3.76±1.57ng/ml, P=0.271). The decline of the level of sPD-L1 was correlated with the effects of good response and progressive disease (PD)(0.49±1.48ng/ml vs. 0.11±0.52ng/ml, P=0.307). As for survival, there was no difference between the decline of level of sPD-L1 and the progress free survival (PFS). Our results indicated that the elevated expression of sPD-L1 of patients with NSCLC was associated with later stages and worse life conditions, and which may correlated with bad clinical response and poor prognosis. EGFR mutation status may affect the expression of sPD-L1. Further studies are needed to determine the role of sPD-L1 as a molecular prognosis marker for the treatment and prognosis of patients with lung cancer." @default.
• W2898117984 created "2018-11-02" @default.
• W2898117984 creator A5018886856 @default.
• W2898117984 creator A5059055529 @default.
• W2898117984 creator A5069881442 @default.
• W2898117984 creator A5080821264 @default.
• W2898117984 creator A5085144700 @default.
• W2898117984 creator A5089792184 @default.
• W2898117984 date "2018-10-01" @default.
• W2898117984 modified "2023-10-01" @default.
• W2898117984 title "P2.01-93 The Analysis of the Soluble Programmed Death-1 of Lung Cancer Patients with Different Characteristics" @default.
• W2898117984 doi "https://doi.org/10.1016/j.jtho.2018.08.1147" @default.
• W2898117984 hasPublicationYear "2018" @default.
• W2898117984 type Work @default.
• W2898117984 sameAs 2898117984 @default.
• W2898117984 citedByCount "0" @default.
• W2898117984 crossrefType "journal-article" @default.
• W2898117984 hasAuthorship W2898117984A5018886856 @default.
• W2898117984 hasAuthorship W2898117984A5059055529 @default.
• W2898117984 hasAuthorship W2898117984A5069881442 @default.
• W2898117984 hasAuthorship W2898117984A5080821264 @default.
• W2898117984 hasAuthorship W2898117984A5085144700 @default.
• W2898117984 hasAuthorship W2898117984A5089792184 @default.
• W2898117984 hasBestOaLocation W28981179841 @default.
• W2898117984 hasConcept C121608353 @default.
• W2898117984 hasConcept C126322002 @default.
• W2898117984 hasConcept C143998085 @default.
• W2898117984 hasConcept C204232928 @default.
• W2898117984 hasConcept C2776256026 @default.
• W2898117984 hasConcept C2777714996 @default.
• W2898117984 hasConcept C71924100 @default.
• W2898117984 hasConcept C90924648 @default.
• W2898117984 hasConceptScore W2898117984C121608353 @default.
• W2898117984 hasConceptScore W2898117984C126322002 @default.
• W2898117984 hasConceptScore W2898117984C143998085 @default.
• W2898117984 hasConceptScore W2898117984C204232928 @default.
• W2898117984 hasConceptScore W2898117984C2776256026 @default.
• W2898117984 hasConceptScore W2898117984C2777714996 @default.
• W2898117984 hasConceptScore W2898117984C71924100 @default.
• W2898117984 hasConceptScore W2898117984C90924648 @default.
• W2898117984 hasIssue "10" @default.
• W2898117984 hasLocation W28981179841 @default.
• W2898117984 hasOpenAccess W2898117984 @default.
• W2898117984 hasPrimaryLocation W28981179841 @default.
• W2898117984 hasRelatedWork W1511190554 @default.
• W2898117984 hasRelatedWork W1967103478 @default.
• W2898117984 hasRelatedWork W2032912323 @default.
• W2898117984 hasRelatedWork W2087332109 @default.
• W2898117984 hasRelatedWork W2363326412 @default.
• W2898117984 hasRelatedWork W2372561159 @default.
• W2898117984 hasRelatedWork W2375344515 @default.
• W2898117984 hasRelatedWork W2380382254 @default.
• W2898117984 hasRelatedWork W2384212262 @default.
• W2898117984 hasRelatedWork W2390152934 @default.
• W2898117984 hasVolume "13" @default.
• W2898117984 isParatext "false" @default.
• W2898117984 isRetracted "false" @default.
• W2898117984 magId "2898117984" @default.
• W2898117984 workType "article" @default.